CTLA4 and neoplasm: Subsequent clinical24 and pre‐clinical studies25, 26 have shown that co‐administration of LMB‐100 facilitates tumor response to anti‐CTLA4 and anti‐PD1 therapies, however, specific mediators of immune response induced by LMB‐100 administration have not been identified.